Jin Jie, Zhao Xueyun, Deng Miao, Du Lingyan
School of Nursing and Health Care, Leshan Vocational and Technical College, Leshan, Sichuan, China.
Department of Breast and Thyroid Surgery, The People's Hospital of Leshan, Leshan, Sichuan, China.
Front Oncol. 2025 Jun 4;15:1582862. doi: 10.3389/fonc.2025.1582862. eCollection 2025.
Breast cancer (BC) is a significant malignancy characterized by a high global incidence and a propensity for recurrence. Absorption, distribution, metabolism, and excretion (ADME) genes comprise a collection of genes that participate in the drug ADME. Understanding the role and prognostic value of ARGs (ADME related genes) in BC advancement is critical for personalized therapy. Therefore, an ARPS (ADME related prognostic signature) was created in this study to examine the clinical implications of ARGs in patients with BC.
A multi-omics investigation of ADME-related genes in BC was conducted using bulk RNA sequencing, single-cell RNA sequencing, and spatial transcriptome data. According to the expression profiles of ADME-related differentially expressed genes (DEGs), the ARPS was calculated, and all patients were stratified based on their risk scores. A prediction model was then created using Cox regression and stepAIC analyses. This model divided all patients into HR (High risk) and LR (Low risk) groups following the median risk score. Bioinformatics analyses were conducted to estimate the risk signature's predictive capacity.
This study identified five ARGs (SLC7A5, HSD11B1, ADHFE1, GSTM2, and TAP1) correlated with BC prognosis. The risk signature in the TCGA-BRCA, METABRIC, and GSE58812 cohorts revealed robust predictive accuracy for 1-, 3-, and 5-year survival. Compared to the gene signature alone, the nomogram integrating the ARPS and clinical parameters demonstrated improved prognostic performance. Immune infiltration analysis revealed a high level of immune checkpoint related gene expression and immune score in patients with ARPS LR, suggesting potential implications for immunotherapy responses.
The findings highlight the prognostic significance of ARPS in BC and its potential utility in guiding personalized treatment strategies. Combining ARPS with clinical parameters enhances prognostic accuracy and may help patients with BC make clinical decisions.
乳腺癌(BC)是一种重要的恶性肿瘤,全球发病率高且易于复发。吸收、分布、代谢和排泄(ADME)基因是一组参与药物ADME过程的基因。了解ADME相关基因(ARGs)在BC进展中的作用和预后价值对于个性化治疗至关重要。因此,本研究创建了一个ADME相关预后特征(ARPS),以研究ARGs在BC患者中的临床意义。
利用批量RNA测序、单细胞RNA测序和空间转录组数据对BC中与ADME相关的基因进行多组学研究。根据ADME相关差异表达基因(DEGs)的表达谱计算ARPS,并根据风险评分对所有患者进行分层。然后使用Cox回归和stepAIC分析创建预测模型。该模型根据中位风险评分将所有患者分为高风险(HR)和低风险(LR)组。进行生物信息学分析以评估风险特征的预测能力。
本研究确定了五个与BC预后相关的ARGs(SLC7A5、HSD11B1、ADHFE1、GSTM2和TAP1)。TCGA-BRCA、METABRIC和GSE58812队列中的风险特征显示出对1年、3年和5年生存率的强大预测准确性。与单独的基因特征相比,整合ARPS和临床参数的列线图显示出更好的预后性能。免疫浸润分析显示,ARPS LR患者的免疫检查点相关基因表达和免疫评分较高,提示对免疫治疗反应的潜在影响。
研究结果突出了ARPS在BC中的预后意义及其在指导个性化治疗策略方面的潜在效用。将ARPS与临床参数相结合可提高预后准确性,并可能帮助BC患者做出临床决策。